Drug intelligence / Profile preview

NRX-1074

Development stage: Preclinical
Lead developer: Allergan
Modality: Small Molecules
Administration: Intravenous, Oral

Overview

NRX-1074 is a small molecule activator of the nuclear receptor Nurr1 (NR4A2) currently in preclinical development by NurrOn Pharmaceuticals for the treatment of Parkinson's disease. Nurr1 is a transcription factor critical for the maintenance and survival of dopaminergic neurons in the midbrain. NRX-1074 exerts its therapeutic potential through a dual mechanism of action: it increases the transcriptional activation of genes essential for dopaminergic function and enhances the transrepression of neurotoxic proinflammatory genes. By targeting Nurr1, NRX-1074 aims to provide neuroprotection and restore dopaminergic signaling, potentially slowing disease progression in Parkinson's patients. The compound is currently undergoing IND-enabling studies.

Targets

NMDAR (Glutamate receptor ionotropic, NMDA)

Beyond the preview

Go deeper on NRX-1074.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NRX-1074.

Explore the full profile